New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR

The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF) have announced a partnership to enhance global antibiotic access. GDF will integrate GARDP’s antibiotic portfolio to improve affordable and appropriate access for patients and health systems, especially in low- and middle-income countries. This partnership aims to reduce wastage, lower prices, and accelerate delivery for better patient outcomes and cost-effective healthcare. GDF, the largest procurer of tuberculosis products, will also benefit patients with non-TB bacterial infections. The partnership reflects the growing need to address antimicrobial resistance through global coordination.